NCT00202930View on ClinicalTrials.gov

Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

February 5, 2009

Conditions

NeuroblastomaOpsoclonus-myoclonus

Interventions

DRUG

anti-CD20 (Rituximab)

4 weekly doses of IV rituxan at 375 mg/m2 on days 1, 8, 15 and 22

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Jean M. Tersak, M.D.

OTHER